| Date |
Title |
| 16 Jul. 2026 |
Illumina expands Billion Cell Atlas program with new AI drug developers |
| 9 Jul. 2026 |
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 |
| 9 Jul. 2026 |
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer |
| 23 Jun. 2026 |
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors |
| 8 Jun. 2026 |
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution |
| 28 May 2026 |
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research |
| 28 May 2026 |
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research |
| 21 May 2026 |
David P. King elected to Illumina's Board of Directors |
| 19 May 2026 |
Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact |
| 30 Apr. 2026 |
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 |
| 16 Apr. 2026 |
DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows |
| 14 Apr. 2026 |
Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease |
| 9 Apr. 2026 |
Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026 |
| 2 Apr. 2026 |
Illumina Announces Changes to Board of Directors |
| 18 Mar. 2026 |
Illumina and Labcorp expand collaboration to broaden access to precision oncology testing |
| 16 Mar. 2026 |
Illumina advances preventive genomics through strategic consortium with Veritas Genetics |
| 5 Mar. 2026 |
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering |
| 27 Feb. 2026 |
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida |
| 25 Feb. 2026 |
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics |
| 24 Feb. 2026 |
Illumina launches TruPath Genome, setting a new standard in genomic insight |
| 23 Feb. 2026 |
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility |
| 17 Feb. 2026 |
Illumina To Webcast Upcoming Investor Conference |
| 5 Feb. 2026 |
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 |
| 3 Feb. 2026 |
Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally |
| 30 Jan. 2026 |
Illumina completes acquisition of SomaLogic |
| 20 Jan. 2026 |
Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology |
| 13 Jan. 2026 |
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery |
| 13 Jan. 2026 |
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025 |
| 12 Jan. 2026 |
Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026 |
| 8 Jan. 2026 |
Illumina Appoints Dr. Eric Green as Chief Medical Officer |
| 6 Jan. 2026 |
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis |